Journal
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume 7, Issue 2, Pages 85-96Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1758834014567470
Keywords
immune checkpoint modulator; nivolumab; non-small cell lung cancer; programmed death-1; programmed death-1 ligand
Categories
Funding
- National Research Foundation, Singapore
- Singapore Ministry of Education
Ask authors/readers for more resources
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available